Radiopharm announces new data from Phase 0/1 HEAT trial

Radiopharm (RADX) Theranostics announced that new data from the ongoing Phase 0/1 HEAT trial, evaluating 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical therapy, will be presented as a poster at the American Association for Cancer Research, AACR, Annual Meeting 2026, being held April 17-22, 2026 in San Diego, California. Key Findings from the AACR Abstract and Poster: Meaningful tumor uptake of 177Lu-RAD202 was observed at the initial and lowest dose level of 30 mCi, particularly in breast cancer lesions; 177Lu-RAD202 was generally well tolerated in the first three treated patients, with predominantly Grade 1-2 treatment-emergent adverse events; No dose-limiting toxicities or treatment discontinuations due to adverse events were observed; Organ-level absorbed radiation doses were within expected and clinically acceptable ranges, supporting continued dose escalation